Gastric Cancer
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 15, 2003; 9(1): 54-58
Published online Jan 15, 2003. doi: 10.3748/wjg.v9.i1.54
Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation
Jing Lan, Yong-Yan Xiong, Yi-Xian Lin, Bi-Cheng Wang, Ling-Ling Gong, Hui-Sen Xu, Guang-Song Guo
Jing Lan, Yong-Yan Xiong, Yi-Xian Lin, Bi-Cheng Wang, Ling-Ling Gong, Hui-Sen Xu, Guang-Song Guo, Department of Pathology, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei Province, China
Author contributions: All authors contributed equally to the work.
Supported by the National Science Fund of Hubei Province, No. 98J087 and the Department of Health of Hubei Province, No.WJ01572
Correspondence to: Dr. Jing Lan, Department of Pathology, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei Province, China. lanjing_2002@hotmail.com
TelepHone: +86-27-87661547
Received: March 12, 2002
Revised: March 23, 2002
Accepted: April 20, 2002
Published online: January 15, 2003

Abstract

AIM: To investigate the relationship between Helicobacter pylori (H. pylori) infection and the expressions of the p53, Rb, c-myc, bcl-2 and hTERT mRNA in a series of diseases from chronic gastritis (CG), intestinal metaplasia type I or II (IMI-II), intestinal metaplasia type III (IMIII), mild or modest dysplasia (DysI-II), severe dysplasia (DysIII) to gastric cancer (GC) and to elucidate the mechanism of gastric carcinogenesis relating to H. pylori infection.

METHODS: 272 cases between 1998 and 2001 were available for the study including 42 cases of CG, 46 cases of IMI-II, 25 cases of IMIII, 48 cases of DysI-II, 27 cases of DysIII, 84 cases of GC. H. pylori infection and the expressions of p53, Rb, c-myc, bcl-2 were detected by means of streptavidin-peroxidase (SP) immunohistochemical method. HTERT mRNA was detected by in situ hybridization(ISH).

RESULTS: The expressions of p53, Rb, c-myc, hTERT mRNA and bcl-2 were higher in the GC than in CG, IM, Dys. The expression of c-myc was higher in IMIII with H. pylori infection (10/16) than that without infection (1/9) and the positive rate in DysI-II and DysIII with H. pylori infection was 18/30 and 13/17, respectively, higher than that without infection (4/18 and 3/10, respectively). In our experiment mutated p53 had no association with H. pylori infection, the expression of Rb was associated with H. pylori infection in GC, but the p53-Rb tumor-suppressor system abnormal in DysI-II cases, DysIII and GC cases with H. pylori infection was 21/30, 15/17 and 48/48 respecively, higher than non-infection groups (4/18, 3/10, 28/36). Furthermore the level of hTERT mRNA in GC with H. pylori infection (47/48) was higher than that without infection (30/36), however the relationship between bcl-2 and H. pylori was only in IMIII. C-myc had a close association with hTERT mRNA in DysIII and GC (P = 0.0253, 0.0305 respectively).

CONCLUSION: In the gastric carcinogenesis, H. pylori might cause the severe imbalance of proliferation and apoptosis in the precancerous lesions (IMIII and GysIII) first, leading to p53-Rb tumor-suppressor system mutation and telomerase reactivation, and finally causes gastric cancer.




INTRODUCTION

Gastric cancer is one of the most fatal malignancies and in the world about 628000 persons die of it every year. A close association between Helicobacter pylori (H. pylori) and gastric cancer has been found[1-14], mainly on the basis of seroepidemiological data. Recently the animal models that developed gastric cancer owing to H. pylori infection provided powerful evidence[15]. Although H. pylori has been classified as a type I carcinogen for gastric cancer by the International Agency for Research on Cancer (IARC)[16], the exact nature and strength of the association with gastric cancer has remained indistinct.

A two-stage pattern has been introduced to explain the escape from senescence of the cultured human cells[17,18]. The mortality stage 1 (M1) mechanism causes senescence, where normal human diploid cells become incapable of further division. However this cessation of cellular division can be overcome by the inactivation of human tumor suppressor genes p53 and Rb in fibroblasts[18,19] that are mutated in a variety human neoplasm. In non-neoplastic cells, wild type p53 modulates cell proliferation and differentiation by regulating the transcription of several gene products, inducing p21waf1 expression which acts as a regulator of the cell cycle at the G1 checkpoint[20,21], and plays a crucial role in repairing damaged DNA through inducing GADD45 (growth arrest and DNA damage)[22]. Moreover p53 induces the Bax gene, which is followed by apoptosis, in contrast to bcl-2[23]. The cells which have overcame the M1 mechanism are able to divide until crisis occurs, which is caused by the mortality stage2 (M2) mechanism. It is difficult for human cells to escape from this crisis, but in rare instances some populations can achieve immortality by overcoming this M2 mechanism through the reactivation of the enzyme telomerase[24-29]. Telomerase is a unique ribonucleoprotein enzyme that is responsible for adding the telomic repeats onto the 3’ end of chromosomes and composed of a catalytic protein submit (hTERT, for human telomerase reverse transcription) and a template RNA (TR), and hTERT is the rate-limiting enzyme in the telomerase complex[30-34].

From all the above it is apparent that the understanding of the association of H. pylori infection with some genes (for example p53, Rb) as well as telomerase can contribute to the elucidation of the mechanisms that regulate the development of gastric cancer. The aim of the present study, therefore, was to examine this association by detecting the expressions of H. pylori, hTERT, p53, Rb, c-myc and bcl-2 in a series of gastric diseases.

MATERIALS AND METHODS
Patients

Two hundred seventy-two patients (174 men, 98 women, ranging in age from 21 to 80 years, mean 54.22 years) underwent endoscopy (noncancerous patients) or curative gastrectomy (gastric cancer patients) in our hospital between 1998 to 2001, including 42 cases of CG, 46 cases of IMI-II, 25 cases of IMIII, 48 cases of DysI-II, 27 cases of DysIII, 84 cases of GC diagnosed according to the updated Sydney System[35] and the Japanese Research Society for Gastric Cancer[36]. No patients had received chemotherapy or radiation therapy before surgery.

All specimens were fixed in 10% buffered neutral formalin and embedded in paraffin and serial sections (4 μm thick).

Histochemical staining

Hematoxylin-eosin (HE) staining was used for the histopathological diagnosis, evaluation and grading of gastritis, atropHy, intestinal metaplasia, dysplasia and cancer. High iron diamine (HID)-alcian blue (AB) (pH2.5)-periodic acid schiff (PAS) method was used to distinguish sulpHates, neutral and acid mucus, which were stained brown-black, red and blue respectively. Using both morpHological and histochemical criteria, the cases of intestinal metaplasia were classified into three types[37].

Immunohistochemistry

Was performed using the streptavidin-peroxidase (sp) method. The following primary antibodies and the kit were used: monoclonal antibodies against p53, Rb, c-myc, bcl-2 and the kit (Maixin-Bio, Fujian), polyclonal antibodies against H. pylori (antibody, diagnostica Inc. USA). Dewaxed sections were heated in a microwave oven (700 W) for 12 min to retrieve the antigens and cooled to room temperature. Endogenous peroxide was blocked by 3% hydrogen peroxide (H2O2) for 15 min in methanol. After being washed with pHospHate-buffered-saline (PBS, 0.01 M), the sections were further blocked by 10% rabbit serum for 15 min to reduce nonspecific antibody binding and then incubated with the primary antibodies of p53, Rb, c-myc, bcl-2 or H. pylori (1:60 dilution) at 4 °C overnight. After being washed with PBS for 2 × 5 min, the sections were incubated with the secondary anti-mouse immunoglobulin (Ig) conjugated with biotin at room temperature for 15 min, washed again with PBS, followed by incubation with streptavin-peroxidase complex for 15 min. The reaction products of peroxidase were visualized by incubation with 0.05 M Tris-HCL buffer (pH7.6) containing 20 mg 3, 3’-diaminobendizine (Maixin-Bio, Fujian) and 100 μl 5% hydrogen peroxide per 100 mL. Finally, the sections were counterstained for nuclei by hematoxilin solution. To examine the specificity of immunostaining, PBS was used to replace the primary antibodies as the control. The assessment of all the samples was conducted by an observer who did not know any details of this study by calculating the average ratio of positive cells (the nuclei or the plasma, staining brown-yellow) under ten 400 × microscopes. If the ratio was more than 10%, this sample was considered positive. However the H. pylori immunostaining was assessed positive as long as the brown-black dotish, stake or bend material was stained on the surface of mucosa or in the gland’s cave.

In situ hybridization

(ISH) was used to detect hTERT (human tolomerase reverse transcriptase) mRNA. The probe (5’-CCCAG GCGCC GCACG AACGT GGCCA GCGGC-3’) and the kit were bought from Boster Bio (Wuhan). Dewaxed sections were incubated with 3% hydrogen peroxide for 30 min to reduce the non-specific binding and then with 1 μg/ml pepsin for 5-8 min to improve the penetration of the probe. The prehybridization was performed at 40 °C for 3 h to enhance hybridization efficiency, and the hybridization was conducted in a 42 °C water bath with each section covered with a coverslip, then the thorough washing procedure was followed: 2 × SSC (sodium chloride and sodium citrate) at 37 °C for 15 min, 0.5 × SSC for 15 min, 0.2 × SSC for 15 min. Then the sections were visualized according to the kit manufacturer’s instructions. We calculated the positive cells ratio to assess the positive sample by calculating the average ratio of positive cells (the plasma was stained brown-yellow) under ten 400 × microscopes. If the ratio was more than 10%, this sample was considered positive.

Statistics analysic

The chi-square test and the Fisher’s exact probability test were used to compute the frequencies by SPSS 10.0 for Windows. P < 0.05 was considered to be statistically significant.

RESULTS

With the development of the diseases from CG, IM, Dys to GC, the positive expressions of p53, Rb, c-myc, bcl-2 and hTERT mRNA were augmented significantly (Table 1). In particular, the frequencies of Rb, c-myc and hTERT mRNA in IMIII (8/25, 11/25, 4/25, respectively) were statistically higher than those in IMI-II (4/46, 8/46, 1/46, respectively) (P < 0.05). The expressions of all variables in GC were statistically higher than in DysIII and IMIII, higher in DysIII e than in IMIII (P < 0.05). In general the frequencies of them in H. pylori infection groups were higher than those in non-infection groups. The expression of c-myc was 10/10, 18/30, 13/17 in IMIII, DysI-II and DysIII with H. pylori infection respectively, higher than non-infection group (1/9, 4/18, 3/10, respectively). In our experiment mutated p53 had no association with H. pylori infection, the expression of Rb was associated with H. pylori infection in GC, but the p53-Rb tumor-suppressor system abnormal in DysI-II cases, DysIII and GC cases with H. pylori infection was 21/30, 15/17 and 48/48, respectively, higher than that in non-infection groups (4/18, 3/10, 28/36, respectively). The association between bcl-2 and H. pylori only existed in IMIII (9/16, 1/9). The expression of hTERT mRNA in GC with H. pylori infection was 47/48, higher than non-infection group (30/36) (Table 2). We also found the association between c-myc and hTERT mRNA in GC and DysIII (P < 0.05) (Table 3).

Table 1 Expressions of c-myc, bcl-2, p53, Rb and hTERTmRNA in the different gastric diseases (%).
GCIMI-IIIMIIIDysI-IIDysIIIGC
c-myc5 (11.90)8 (17.39)11 (44.00)22 (45.83)16 (59.26)74 (88.09)
bcl-23 (7.14)17 (36.96)10 (40.00)24 (50.00)18 (66.67)55 (65.48)
p530 (0.00)3 (6.52)5 (20.00)14 (29.17)10 (37.04)64 (76.19)
Rb3 (7.14)4 (8.70)8 (32.00)14 (29.17)12 (44.44)61 (72.62)
HTERTmRNA0 (0.00)1 (2.17)4 (16.00)10 (16.67)12 (44.44)78 (92.86)
Table 2 The correlations between p53, Rb, c-myc, hTERT, bcl-2 and H. pylori in benign diseases and gastric cancer.
H. pyloriCG
IMI-II
IMIII
DysI-II
DysIII
GC
+(31)-(11)+(32)-(14)+(16)-(9)+(30)-(18)+(17)-(10)+(48)-(36)
c-myc507110a118a413a34430
bcl-2301259a11771353817
p5300213212a2643925
Rb3040621139340a21
P53-Rb30416321a415a348a28
hTERT001040829347a30
Table 3 Correlation between c-myc and hTERT in the gastric benign diseases and gastric cancer.
c-mycCG
IMI-II
IMIII
DysI-II
DysIII
GC
(+)(-)(+)(-)(+)(-)(+)(-)(+)(-)(+)(-)
hTERT(+)0010317310a270a7
(-)53773981315236943
DISCUSSION

Gastric cancer occurs after a multi-step process of alterations in oncogenes, tumor-suppressor genes, cell-adhesion molecules, telomerase as well as genetic instability at several microsatellite loci. Studies have demonatrated that H. pylori infection is closely associated with these abnormal alterations. Konturek’s study[38] showed that H. pylori induced apoptosis in gastric mucosa through upregulation of Bax and bcl-2 expression. The bcl-2 gene family plays an important role in regulating apoptosis. In our studies, H. pylori enhanced the expression of c-myc and bcl-2 significantly in IMIII (P < 0.05). The c-myc protein is a critical component for the control of normal cell growth, but the altered c-myc activity by translocation, amplification, overexpression, and mutation is widespread in tumor cells and important for multi-step carcinogenesis[39,40]. C-myc is a strong inducer of proliferation and it is believed to be critical for the oncogenic properties. Some studies showed that the abnormal c-myc expression derived cells inappropriately through the cell cycle, leading to uncontrolled proliferation, a characteristic of neoplastic cells. Form our study we found that H. pylori infection caused a higher proliferation and a lower apoptosis in IMIII than in CG and IMI-II and accelerated cell proliferation, leaving a good chance for all kinds of genes and proteins to mutate or overexpress, presumably heightening the genetic instability consistent with the development of carcinoma[41,42].

Mutations in the tumor suppressor genes p53 and Rb are common events in human cancers that exert their control on the cell cycle at the G1-S pHase transition through independent but interconnected pathways[43-50]. Williams’s studies showed that germ-line mutation in p53 and Rb might have cooperative tumorigenic effects in mice[45]. It has been generally accepted that p53 and Rb tumor-suppressor system, including p53, Rb, p16, p15, p14 and p21waf1[51-59], play an important role in carcinogenesis. Some studies observed this pHenomenon that NO (nitric oxide) generated by H. pylori caused p53 mutation at the spot C:G to A:T and at the same time p53 was found mutated at the same spot in IM, Dys and GC, thus H. pylori probably caused p53 mutation. In our study, we found that the expressions of p53-Rb were continually enhanced from chronic gastritis (3/42) to gastric cancer (76/84) and in the DysIII and GC which had a close association with H. pylori (P < 0.05). Chen[60] reported that the mRNA levels of p53-Rb in gastric cancer were significantly lower than those in their non-cancerous tissues using quantitative analysis method. Some studies favored the view that c-myc drove initial proliferation and subsequent differentiation, concomitant with the activation of the p53 G2 checkpoint and also demonstrated that inactivation of the p53-Rb pathway is required for immortalization through overepression of Myc[61,62]. Although c-myc and p53-Rb had no direct association in our study, H. pylori infection might initially provoke the c-myc and bcl-2 more than in non-infection group in IMIII and then inactivate the p53-Rb tumor-suppress system in Dys and they collaborated in GC.

Telomerase activity has been found in 85%-90% of all human cancers but not in adjacent normal cells[27]. It has thus been hypothesized that for a cancer cell to undergo sustained proliferation beyond the limits of cell senescence, it must reactivate telomerase or an alternative mechanism in order to maintain telomeres. This makes telomerase a target not only for the novel etiology agent but also a mark for cancer diagnosis. Many studies showed that telomerase activity was higher in cancers than in non-cancerous tissues and higher in IM than in CG[63-68], which was similar to our results. The association between H. pylori infection and telomerase activity is still controversial. Suzuki’ study[66] indicated that hTERT mRNA which was expressed in precancerous lesions and gastric cancer could be induced at an early stage of gastric carcinogenesis, but it was not correlated with H. pylori. Kuniyasu[69] found that H. pylori evidently caused the release of reactive oxygen species (ROMs) and reactive nitrogen species (NO) which might be strong triggers for “stem cell” hyperplasic in IM, followed by telomere reduction and increased telomerase activity as well as hTERT overexpression. We found in GC hTERT expression was significantly higher in infection group (47/48) than in non-infection group (30/36) but had no association in Dys or IM, maybe because there exist two different genetic pathways to two histological types: intestinal-type and diffuse-type gastric cancer. Some studies showed c-myc could stimulate expression of hTERT and thereby enhance telomerase activity which was an important step in carcinogenesis[70-79]. In our study c-myc had an association with hTERT in Dys and GC, which suggests that H. pylori stimulates telomerase directly or indirectly by the overexpression of c-myc. We did not find the association between hTERT and p53-Rb or bcl-2.

There maybe exit this mechanism of gastric caicinogenesis relating to chronic H. pylori infection, which leads to imbalance of proliferation and apoptosis in the early stage, and furthermore p53-Rb tumor-suppressor system mutation, telomerase reactivation and finally gastric cancer generation. Hence this molecular pathology mechanism should be applied in routine diagnostic procedures, classification systems, disease monitoring, and even prognostic assessment.

ACKNOWLEDGMENTS

The authors thank the faculty of Department of Pathology and Wang Zhifeng of Stomatology of hospital for their excellent technical assistance throughout this investigation.

Footnotes

Edited by Pang LH

References
1.  Sipponen P, Kosunen TU, Valle J, Riihelä M, Seppälä K. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol. 1992;45:319-323.  [PubMed]  [DOI]
2.  Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992;102:720-727.  [PubMed]  [DOI]
3.  Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302-1305.  [PubMed]  [DOI]
4.  Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131.  [PubMed]  [DOI]
5.  Talley NJ, Zinsmeister AR, Weaver A, DiMagno EP, Carpenter HA, Perez-Perez GI, Blaser MJ. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991;83:1734-1739.  [PubMed]  [DOI]
6.  An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet. 1993;341:1359-1362.  [PubMed]  [DOI]
7.  Hansson LE, Engstrand L, Nyrén O, Evans DJ, Lindgren A, Bergström R, Andersson B, Athlin L, Bendtsen O, Tracz P. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology. 1993;105:1098-1103.  [PubMed]  [DOI]
8.  Blaser MJ. Helicobacter pylori and gastric diseases. BMJ. 1998;316:1507-1510.  [PubMed]  [DOI]
9.  Wang TC, Fox JG. Helicobacter pylori and gastric cancer: Koch's postulates fulfilled. Gastroenterology. 1998;115:780-783.  [PubMed]  [DOI]
10.  Vandenplas Y. Helicobacter pylori infection. World J Gastroenterol. 2000;6:20-31.  [PubMed]  [DOI]
11.  Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County,Fujian Province,China. World J Gastroenterol. 2000;6:374-376.  [PubMed]  [DOI]
12.  Zhuang XQ, Lin SR. Research of Helicobacter pylori infection in precancerous gastric lesions. World J Gastroenterol. 2000;6:428-429.  [PubMed]  [DOI]
13.  Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol. 2001;96:16-26.  [PubMed]  [DOI]
14.  Meining A, Bayerdörffer E, Stolte M. [Extent, topograpHy and symptoms of Helicobacter pylori gastrtitis. pHenotyping for accurate diagnosis and therapy]. Pathologe. 2001;22:13-18.  [PubMed]  [DOI]
15.  Fujioka T, Honda S, Tokieda M. Helicobacter pylori infection and gastric carcinoma in animal models. J Gastroenterol Hepatol. 2000;15 Suppl:D55-D59.  [PubMed]  [DOI]
16.  International Agency for research on Cancer. Schistosomes, Liver flukes and Helicobacter pylori. Evaluation of carcinogenic risks to humans. IARC MonograpHEvaluating Carcinogenic Risks to Humans. 1994;61.  [PubMed]  [DOI]
17.  Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol. 1989;9:3088-3092.  [PubMed]  [DOI]
18.  Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res. 1991;196:33-39.  [PubMed]  [DOI]
19.  Shay JW, Wright WE, Brasiskyte D, Van der Haegen BA. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene. 1993;8:1407-1413.  [PubMed]  [DOI]
20.  el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-1174.  [PubMed]  [DOI]
21.  Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995;11:1899-1905.  [PubMed]  [DOI]
22.  Zhan Q, Bae I, Kastan MB, Fornace AJ. The p53-dependent gamma-ray response of GADD45. Cancer Res. 1994;54:2755-2760.  [PubMed]  [DOI]
23.  Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 1994;9:3743-3751.  [PubMed]  [DOI]
24.  Harley CB. Telomere loss: mitotic clock or genetic time bomb. Mutat Res. 1991;256:271-282.  [PubMed]  [DOI]
25.  Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol. 1992;27:375-382.  [PubMed]  [DOI]
26.  Shay JW, Wright WE, Werbin H. Toward a molecular understanding of human breast cancer: a hypothesis. Breast Cancer Res Treat. 1993;25:83-94.  [PubMed]  [DOI]
27.  Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol. 1992;27:383-389.  [PubMed]  [DOI]
28.  Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.  [PubMed]  [DOI]
29.  Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72-76.  [PubMed]  [DOI]
30.  Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.  [PubMed]  [DOI]
31.  Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. The RNA component of human telomerase. Science. 1995;269:1236-1241.  [PubMed]  [DOI]
32.  Kyo S, Takakura M, Tanaka M, Kanaya T, Sagawa T, Kohama T, Ishikawa H, Nakano T, Shimoya K, Inoue M. Expression of telomerase activity in human chorion. Biochem BiopHys Res Commun. 1997;241:498-503.  [PubMed]  [DOI]
33.  Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998;18:65-68.  [PubMed]  [DOI]
34.  Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998;58:1558-1561.  [PubMed]  [DOI]
35.  Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.  [PubMed]  [DOI]
36.  Japanese Research Society for Gastric Cancer: The General Rules for the Gastric Cancer Study, First English Edition Kanehara, Tokyo. 1995;.  [PubMed]  [DOI]
37.  Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol. 1980;33:801-810.  [PubMed]  [DOI]
38.  Konturek PC, Pierzchalski P, Konturek SJ, Meixner H, Faller G, Kirchner T, Hahn EG. Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Scand J Gastroenterol. 1999;34:375-383.  [PubMed]  [DOI]
39.  Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207.  [PubMed]  [DOI]
40.  Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic pHenotype by a single oncogenic lesion. Mol Cell. 1999;3:565-577.  [PubMed]  [DOI]
41.  Conchillo JM, Houben G, de Bruïne A, Stockbrügger R. Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma. Eur J Cancer Prev. 2001;10:307-312.  [PubMed]  [DOI]
42.  Rubio CA, Jónasson JG, Filipe I, Cabanne AM, Hojman R, Kogan Z, Nesi G, Amorosi A, Zampi G, Klimstra D. Gastric carcinomas of intestinal type concur with distant changes in the gastric mucosa. A multicenter study in the Atlantic basin. Anticancer Res. 2001;21:813-818.  [PubMed]  [DOI]
43.  Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature. 1992;359:295-300.  [PubMed]  [DOI]
44.  Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.  [PubMed]  [DOI]
45.  Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994;7:480-484.  [PubMed]  [DOI]
46.  Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.  [PubMed]  [DOI]
47.  Götz C, Montenarh M. p53: DNA damage, DNA repair, and apoptosis. Rev pHysiol Biochem pHarmacol. 1996;127:65-95.  [PubMed]  [DOI]
48.  Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.  [PubMed]  [DOI]
49.  Platz A, Hansson J, Månsson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganäs M, Ringborg U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst. 1997;89:697-702.  [PubMed]  [DOI]
50.  Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res. 1995;55:20-23.  [PubMed]  [DOI]
51.  Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998;12:2984-2991.  [PubMed]  [DOI]
52.  Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997;57:1217-1221.  [PubMed]  [DOI]
53.  Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58:1090-1094.  [PubMed]  [DOI]
54.  Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.  [PubMed]  [DOI]
55.  Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991;51:5520-5525.  [PubMed]  [DOI]
56.  Wang J, Coltrera MD, Gown AM. Abnormalities of p53 and p110RB tumor suppressor gene expression in human soft tissue tumors: correlations with cell proliferation and tumor grade. Mod Pathol. 1995;8:837-842.  [PubMed]  [DOI]
57.  Gleich LL, Li YQ, Biddinger PW, Gartside PS, Stambrook PJ, Pavelic ZP, Gluckman JL. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope. 1996;106:1378-1381.  [PubMed]  [DOI]
58.  Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, Kuzumaki N, Kawakami Y, Benedict WF. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer. 1997;79:1329-1337.  [PubMed]  [DOI]
59.  Ferron PE, Bagni I, Guidoboni M, Beccati MD, Nenci I. Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions. Tumori. 1997;83:587-593.  [PubMed]  [DOI]
60.  Chen YJ, Shih LS, Chen YM. Quantitative analysis of CDKN2, p53 and retinoblastoma mRNA in human gastric carcinoma. Int J Oncol. 1998;13:249-254.  [PubMed]  [DOI]
61.  Pelengaris S, RudolpH B, Littlewood T. Action of Myc in vivo - proliferation and apoptosis. Curr Opin Genet Dev. 2000;10:100-105.  [PubMed]  [DOI]
62.  Dazard JE, Piette J, Basset-Seguin N, Blanchard JM, Gandarillas A. Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size. Oncogene. 2000;19:3693-3705.  [PubMed]  [DOI]
63.  Okusa Y, Ichikura T, Mochizuki H, Shinomiya N. Clinical significance of telomerase activity in biopsy specimens of gastric cancer. J Clin Gastroenterol. 2000;30:61-63.  [PubMed]  [DOI]
64.  Zhang F, Zhang X, Fan D. [Expression of telomere and telomerase in human primary gastric carcinoma]. Zhonghua Binglixue Zazhi. 1998;27:429-432.  [PubMed]  [DOI]
65.  Kameshima H, Yagihashi A, Yajima T, Kobayashi D, Denno R, Hirata K, Watanabe N. Helicobacter pylori infection: augmentation of telomerase activity in cancer and noncancerous tissues. World J Surg. 2000;24:1243-1249.  [PubMed]  [DOI]
66.  Suzuki K, Kashimura H, Ohkawa J, Itabashi M, Watanabe T, Sawahata T, Nakahara A, Muto H, Tanaka N. Expression of human telomerase catalytic subunit gene in cancerous and precancerous gastric conditions. J Gastroenterol Hepatol. 2000;15:744-751.  [PubMed]  [DOI]
67.  Hur K, Gazdar AF, Rathi A, Jang JJ, Choi JH, Kim DY. Overexpression of human telomerase RNA in Helicobacter pylori-infected human gastric mucosa. Jpn J Cancer Res. 2000;91:1148-1153.  [PubMed]  [DOI]
68.  Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med. 2001;33:123-129.  [PubMed]  [DOI]
69.  Kuniyasu H, Yasui W, Yokozaki H, Tahara E. Helicobacter pylori infection and carcinogenesis of the stomach. Langenbecks Arch Surg. 2000;385:69-74.  [PubMed]  [DOI]
70.  Latil A, Vidaud D, Valéri A, Fournier G, Vidaud M, Lidereau R, Cussenot O, Biàche I. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer. 2000;89:172-176.  [PubMed]  [DOI]
71.  Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000;28:669-677.  [PubMed]  [DOI]
72.  Cerni C. Telomeres, telomerase, and myc. An update. Mutat Res. 2000;462:31-47.  [PubMed]  [DOI]
73.  Kumamoto H, Kinouchi Y, Ooya K. Telomerase activity and telomerase reverse transciptase (TERT) expression in ameloblastomas. J Oral Pathol Med. 2001;30:231-236.  [PubMed]  [DOI]
74.  Xu D, Popov N, Hou M, Wang Q, Björkholm M, Gruber A, Menkel AR, Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA. 2001;98:3826-3831.  [PubMed]  [DOI]
75.  Kyo S, Takakura M, Inoue M. Telomerase activity in cancer as a diagnostic and therapeutic target. Histol Histopathol. 2000;15:813-824.  [PubMed]  [DOI]
76.  Eberhardy SR, D'Cunha CA, Farnham PJ. Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J Biol Chem. 2000;275:33798-33805.  [PubMed]  [DOI]
77.  Kitagawa Y, Kyo S, Takakura M, Kanaya T, Koshida K, Namiki M, Inoue M. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res. 2000;6:2868-2875.  [PubMed]  [DOI]
78.  Nozawa K, Maehara K, Isobe K. Mechanism for the reduction of telomerase expression during muscle cell differentiation. J Biol Chem. 2001;276:22016-22023.  [PubMed]  [DOI]
79.  Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M. The correlation of TERT expression with c-myc expression in cervical cancer. Cancer Lett. 2001;168:45-50.  [PubMed]  [DOI]